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Background
The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure may vary from 3% to 92% over a five-year period. Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within the first month of cranial surgery. The use of antiepileptic drugs (AEDs) administered pre-or postoperatively to prevent seizures following cranial surgery has been investigated in a number of randomised controlled trials (RCTs).
Objectives
To determine the efficacy and safety of AEDs when used prophylactically in people undergoing craniotomy and to examine which AEDs are most effective.
Search methods
Searches were run for the original review in January 2012. We performed subsequent searches in September 2012 and up to 04 August 2014. We searched the Cochrane Epilepsy Group's Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE. We did not apply any language restrictions.
Selection criteria
We included RCTs of people with no history of epilepsy who were undergoing craniotomy for either therapeutic or diagnostic reasons. Trials with adequate randomisation methods and concealment were included; these could either be blinded or unblinded parallel trials. We did not stipulate a minimum treatment period, and we included trials using active drugs or placebo as a control group.
Data collection and analysis
Two review authors (JP and JG) independently selected trials for inclusion and performed data extraction and risk of bias assessments. We resolved any disagreements through discussion. Outcomes investigated included the number of patients experiencing seizures (early -occurring within first week following craniotomy, and late -occurring after first week following craniotomy), the number of deaths and the number of people experiencing disability and adverse effects. Due to the heterogeneous nature of the trials, we did not combine data from the included trials in a meta-analysis; we presented the findings of the review in narrative format.
Main results
We included eight RCTs (N = 1602), which were published between 1983 and 2013. Three trials compared a single AED (phenytoin) with a placebo or no treatment. One three-arm trial compared two AEDs (carbamazepine, phenytoin) with no treatment. A second three-arm trial compared phenytoin, phenobarbital and no treatment. Three other trials were head-to-head trials of AEDs (phenytoin vs. valproate; zonisamide vs. phenobarbital) and levetiracetam vs. phenytoin. Of the five trials comparing AEDs with controls, only one trial reported a significant difference between AED treatment and controls for early seizure occurrence. All other comparisons were non-significant. Of the head-to-head trials, none reported statistically significant differences between treatments for either early or late seizures. One head-to-head trial showed an increase in the number of deaths following one AED treatment compared to another AED treatment. Incidences of adverse effects of treatment were poorly reported, and the most trials reported no significant differences between treatment groups. However data on adverse events were limited.
Authors' conclusions
There is little evidence to suggest that AED treatment administered prophylactically is effective or not effective in preventing postcraniotomy seizures. The current evidence base is limited due to the differing methodologies employed in the trials and inconsistencies in reporting of outcomes. Further evidence from good-quality, contemporary trials is required in order to assess the effectiveness of prophylactic AED treatment compared to control groups or other AEDs in preventing post-craniotomy seizures properly.
P L A I N L A N G U A G E S U M M A R Y
The use of antiepileptic drugs to prevent seizures following brain surgery Antiepileptic drugs (AEDs) have been used in trials to prevent seizures occurring after surgery in people with no previous history of epilepsy. A small number of trials have compared different AED treatments against each other, while others have compared AEDs to a placebo or no treatment group.
This Cochrane Review examines the differences between the AED treatments in relation to number of patients experiencing seizures, number of patient deaths and number of adverse effects experienced following craniotomy surgery (a type of brain surgery most commonly used to remove brain tumours).
We carried out a search of databases up to 04 August 2014. Eight trials met our inclusion criteria, and included 1602 people with partial epilepsy.
We did not find any evidence to suggest that preventative AED treatments are effective in reducing the number of seizures which occurred post-surgery, deaths or adverse effects.
Taking all the studies together, we judged the quality of the study methods to be unclear due to the lack of details present in the reports. Further good quality studies are needed to validate the findings mentioned above.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antiepileptic drugs as prophylaxis for post-craniotomy seizures 
B A C K G R O U N D
Description of the condition
The incidence of epilepsy following supratentorial craniotomy for non-traumatic pathology has been estimated to be 15% to 20% (Foy 1981) ; however, due to the nature of the underlying disease for which surgery is undertaken, the risk of post-craniotomy seizures may vary from 3% to 92% over a five-year period. It is likely that such seizures may cause epilepsy in previously unaffected people. The probability of de novo seizures occurring in people who have no history of epilepsy decreases over time. The highest incidence of postoperative epilepsy (two-thirds of the seizures) occurs within the first month after cranial surgery (North 1983) , and 75% of those who do develop epilepsy will do so within one year of surgery. Few people (approximately 8%) have their first seizure more than two years after surgery. The risk of seizures for particular groups of people is higher; for example for those with an arteriovenous malformation who have had a spontaneous intracerebral haematoma, the overall risk does not fall below 10% between year two and five after surgery, while people who suffered from an abscess continue to run a risk of developing epilepsy (92%) after five years (Shaw 1991).
Description of the intervention
Due to the risk of postoperative seizures, the prophylactic use of antiepileptic drugs (AEDs) has been advocated for patients undergoing cranial surgery. However, it is also argued that AEDs should not be used prophylactically, but should only be administered following at least one seizure (Temkin 2002) . Other investigators maintain that early postoperative seizures do not justify the diagnosis of epilepsy and only late seizures are considered to be true epilepsy (Manaka 2003) .
How the intervention might work
Uncontrolled retrospective trials support the use of AED treatment in patients with a predisposition towards developing postoperative seizures (Matthew 1980) and data from pathological trials suggest that certain AEDs could have a neuro-protective action on damaged cerebral cortex (Calabresi 2003) .
Why it is important to do this review
To inform decision-making regarding the prophylactic use of AEDs for people undergoing craniotomy, reliable high-quality evidence is required. Benefits and harms and any trade-offs between these need to be examined carefully. Potential benefits include reduced short-term seizure recurrence, reduced long-term epilepsy rates, and better surgical outcome and quality of life. Harms include adverse effects and poorer surgical outcome. This Cochrane Review will provide a summary of the currently available evidence from randomised controlled trials (RCTs) regarding the prophylactic use of AEDs for people undergoing craniotomy by examining the following outcomes: occurrence of early and late seizures, occurrence of death, functional disability and occurrence of adverse events.
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review 
Types of participants
People of any age and either gender undergoing a supratentorial or infratentorial craniotomy for either therapeutic or diagnostic reasons for all pathologies, who have had no history of seizures or prior exposure to AEDs. We excluded people with traumatic brain injuries from this review.
Types of interventions
1. The active treatment group receive treatment with any AED administered prior to or immediately post craniotomy.
2. The control group receive matched PCB, different AED or no treatment.
Types of outcome measures
Primary outcomes
Early seizures
The proportion of people experiencing seizures occurring within the first week following craniotomy.
Late seizures
The proportion of people experiencing seizures after the first week from craniotomy including follow-up period of one, two and five years postoperatively from craniotomy.
Secondary outcomes
Death
The proportions of deaths occurring within the treatment period or during follow-up.
Functional outcome
The proportion of people experiencing disability (partially or fully dependent on others in normal activities of daily living).
Adverse effects
The proportion of people who experience any of the following adverse events:
• Skin irritation;
In addition, we decided to look at the proportion of people experiencing the five most common adverse effects mentioned in the included trials if these differed from the list above.
Search methods for identification of studies Electronic searches
Searches were run for the original review in January 2012. Subsequent searches were run in September 2012 and August 2014. For the latest update we searched: 1. the Cochrane Epilepsy Group Specialized Register (04 August 2014) using the search strategy outlined in Appendix 1.
2. the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), 04 August 2014, using the search strategy outlined in Appendix 2.
3. MEDLINE (Ovid, 1946 to 04 August 2014) using the search strategy outlined in Appendix 3. We did not impose any language restrictions.
Searching other resources
We reviewed the reference lists of retrieved trials to check for additional reports of relevant studies.
Data collection and analysis
Selection of studies
Two review authors (JP and JG) independently assessed articles for inclusion. We resolved any disagreements through discussion, and failing this, we sought the opinion of a third review author (AM). The same review authors independently carried out data extraction and assessed risk of bias. Again, any disagreements were resolved through discussion. Failing this, we sought the opinion of the third review author (AM).
Data extraction and management
We extracted the following information for each trial using a data extraction sheet: For all trials we attempted to confirm the above information with trial authors/researchers and sponsors.
Assessment of risk of bias in included studies
Two review authors (JP and JG) independently assessed the risk of bias for each trial using the Cochrane 'Risk of bias' table, as described in Higgins 2002. Any disagreements were discussed and resolved. We rated the included trials as adequate, inadequate or unclear on six domains applicable to RCTs: randomisation method, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. Also, we created a 'Summary of findings' table.
Measures of treatment effect
We have presented treatment effects as they were given in the original reports.
Assessment of heterogeneity
We assessed clinical heterogeneity by examining the differences in trial characteristics in order to inform decisions regarding the combination of trial data.
Assessment of reporting biases
Reporting biases, such as publication bias, were examined by identifying certain aspects of each trial (e.g. sponsors of the research, research teams involved).
Data synthesis
We synthesised data narratively as we considered meta-analysis inappropriate given the differences across trials in AED treatment, trial intervention characteristics and control groups (see Table 1 ). Data under each comparison listed below were minimal and we could not combine these data across all outcomes. We have discussed the following comparisons in the narrative:
1. 
R E S U L T S Description of studies Results of the search
Our searches identified 101 records from the databases outlined in the Electronic searches section. We identified 10 additional records through the reference lists of the included trials. Sixty-nine records remained after we removed duplicates, and we screened all for inclusion in the review. We excluded 43 records at this point, leaving 26 full-text articles to be assessed for eligibility. Following this, we excluded 15 texts (see Figure 1 and Characteristics of excluded studies for reasons of exclusion). We included eight trials from ten reports in a narrative synthesis and one record is awaiting classification (see Characteristics of studies awaiting classification). 
Included studies
We identified eight parallel RCTs (Beenen 1999; Foy 1992; Franceschetti 1990; Fuller 2013; Lee 1989; Nakamura 1999; North 1983; Wu 2013) examining the effectiveness of AEDs on post-craniotomy seizures. The treatment periods varied across trials from three days to 24 months; in one trial the treatment period was unclear (Franceschetti 1990) . People were excluded from five of the trials if they were taking AEDs already and if they had a history of epilepsy (Beenen 1999; Foy 1992; Lee 1989; Nakamura 1999; North 1983) . One trial (Franceschetti 1990) included both people who had preoperative seizures (Group A) and those who did not (Group B); Group A and Group B were analysed separately compared to controls. We only extracted data pertaining to Group B to be included within this Cochrane Review as Group A did not meet our inclusion criteria. Beenen 1999 was a single-centre trial with a treatment period of 12 months. People aged between 18 and 80 years who were undergoing supratentorial craniotomy were eligible to be randomised. The trial authors randomised 100 patients: 50 people to phenytoin 100 mg (PHT) and 50 people to valproate 500 mg (VAL) treatment. Both treatments were administered intravenously immediately post operation in a recovery room. Outcomes reported included early and late seizures, death and adverse effects. No data were reported for functional outcome. Foy 1992 was a single-centre, head-to-head (active drug comparison) trial with a treatment phase of either six or 24 months, and follow-up occurred for a minimum of three years to a maximum of eight years. People aged over 16 years undergoing supratentorial craniotomy were eligible to be randomised. The trial authors randomised 276 patients: 50 to carbamazepine (CBZ) for a six-month treatment period, 56 to CBZ for a 24-month treatment period, 55 to PHT for a six-month treatment period, 56 to PHT for a 24-month treatment period and 59 to no treatment. Administration of CBZ (200 mg) was every six hours for the 24 hours immediately pre-operation and every eight hours thereafter; PHT (15 mg/kg) was administered 24 hours pre-operation and increased to 100 mg eight hourly thereafter. Outcomes reported included number of patients with seizures and death. No differentiation was made between early and late seizures, and no data were reported for functional outcome or adverse effects. All data were reported at six months into the treatment. Franceschetti 1990 was a single-centre, head-to-head, three-arm trial that included a 'no treatment' group. People undergoing surgery for supratentorial neoplasms were randomised and patients with a history of seizures formed Group A and patients who had no history of seizures formed Group B. Sixty-three Group B patients were randomised: 25 to phenobarbital (PB), 16 to PHT and 22 to no treatment. The PB (4 mg/kg) was intravenously administered daily for five days and then decreased to 2 mg/kg daily via oral administration. PHT (10 mg/kg) was intravenously administered daily for five days and then decreased to 5 mg/kg daily via oral administration. Outcomes reported included early and late seizures, and minimal data on adverse effects were presented. Fuller 2013 was a single-centre, head-to-head, two-arm trial with a treatment period of 90 days. Eighty-one people undergoing craniotomy were randomised: 39 to levetiracetam (LEV) and 42 to PHT. LEV (250 to 1000 mg) was administered twice daily either intravenously or orally and PHT (1000 mg) daily in the same form. Outcomes measured included discontinuation of treatment due to side effects and clinically undesirable event and seizure occurrence. Lee 1989 was a PCB-controlled trial with a treatment period of three days. People receiving intracranial, supratentorial surgery were eligible to take part in the trial. Four hundred patients were selected for participation and randomised, and 26 early deaths occurred leaving 189 people randomised to PHT and 185 people to PCB. PHT (15 mg/kg) was administered 15 to 20 minutes prior to wound closure followed by intravenous PHT (5 to 6 mg/kg) three times daily for the first three postoperative days. Outcomes measured included number of seizures occurring within the three days of the trial. Data for late seizures, death, functional outcome and adverse effects were not recorded. Nakamura 1999 was a multi-centre, head-to-head trial with a treatment phase of one year and a follow-up of two years without medication. People undergoing craniotomy for cerebral tumours, cerebrovascular disease and head trauma were selected for eligibility. Two hundred and seventy-eight patients were randomised: 141 to zonisamide (ZNS, 100 mg twice daily) and 137 to PB (40 mg twice daily). Both drugs were administered orally, at least one week before surgery and then increased (ZNS to 100 mg three or four times daily and PB to 40 mg three or four times daily) for one year followed by a tapering period of six months (three months at 100 mg (ZNS) or 40 mg (PB) twice daily then three months at 100 mg (ZNS) or 40 mg (PB) once daily). Outcomes reported were seizure frequency, death (during follow-up period only) and adverse effects. No data were collected on functional outcome. North 1983 was a single-centre, PCB-controlled trial with a treatment period of 12 months. People undergoing supratentorial operation (either burr hole, craniectomy or osteoplastic flap procedures) were eligible for inclusion for the trial. The trial authors randomised 281 patients: 140 to PHT and 141 to PCB. PHT (250 mg twice daily) was administered in a recovery room intravenously, and then continued with oral medication (100 mg three times daily) for one year. Outcomes reported were early and late seizures, death and adverse effects. No data were collected on functional outcomes. Wu 2013 was a single-centre, no treatment controlled trial with a treatment period of seven days. People with supratentorial tumours were eligible for inclusion in the trial. The trial authors randomised 123 people to either PHT (n = 62) or a no treatment control group (n = 61). PHT (100 mg) every eight hours was administered to the treatment group. Outcomes reported were seizure occurrence and adverse reactions.
Excluded studies
Overall we excluded 15 full-text articles for the following reasons: seven were not RCTs (Baker 1995; Boarini 1985; De Santis 1996; Grobelny 2009; Hayashi 1999; Murri 1992; Notani 1984) , two were review articles (Manaka 2003; Shaw 1991) , and six studies had participants that did not meet our inclusion criteria (De Santis 2002; Levati 1996; Lim 2009; Temkin 1990; Temkin 1999; Tsolaki 1987) . We categorised one study (Zhang 2000) in the Studies awaiting classification section as it was unavailable.
Risk of bias in included studies
Allocation
For sequence generation, we rated two studies at low risk of bias (Beenen 1999; Foy 1992) , six studies at unclear risk of bias ( Franceschetti 1990; Fuller 2013; Lee 1989; Nakamura 1999; North 1983; Wu 2013) and no studies were rated at high risk of bias. For allocation concealment, we rated one study at low risk of bias (Beenen 1999) and seven studies (Foy 1992; Franceschetti 1990; Fuller 2013; Lee 1989; Nakamura 1999; North 1983; Wu 2013) at unclear risk of bias due to the lack of detail of these methods.
Blinding
Four studies were rated at low risk of bias due to the methods of blinding employed (Beenen 1999; Lee 1989; Nakamura 1999; North 1983) . We rated two studies at unclear risk of bias (Franceschetti 1990; Fuller 2013) and two studies at high risk of bias as only the outcome assessor appeared to be blinded in one trial and the other was unblinded (Foy 1992; Wu 2013) .
Incomplete outcome data
We rated three studies at low risk of bias due to no missing data (Beenen 1999; North 1983; Wu 2013) . Five studies were rated at unclear risk of bias due to lack of detail regarding the analysis (Foy 1992; Franceschetti 1990; Fuller 2013; Lee 1989 ; Nakamura 1999). We did not rate any studies at high risk of bias.
Selective reporting
We rated all of the included studies at unclear risk of bias due to the lack of protocols available for comparison (Beenen 1999; Foy 1992; Franceschetti 1990; Fuller 2013; Lee 1989; Nakamura 1999; North 1983; Wu 2013) . All protocols were requested from the study authors if contact details were available, however we did not receive any responses.
Other potential sources of bias
Six studies were rated at low risk of bias as we did not identify any other bias (Beenen 1999; Franceschetti 1990; Fuller 2013; Lee 1989; Nakamura 1999; North 1983) . We rated two studies at unclear risk of bias (Foy 1992 
Effects of interventions
See: Summary of findings for the main comparison Antiepileptic drugs as prophylaxis for post-craniotomy seizures Due to the variety of head-to-head drug comparisons within the included trials, we have presented the effects of the interventions by outcome measure as opposed to comparisons under trial. See Table 2 and Table 3 for individual trial results and Table 1 
Adverse effects
Four trials reported information on adverse effects. In the Beenen 1999 trial, 4/50 people experienced a skin reaction, 3/50 people experienced liver dysfunction, 1/50 people experienced thrombopenia and there was one case of nausea within the PHT group (N = 50). In the VAL group there were three cases of liver dysfunction, and one case of a rise in liver enzymes (N = 50). Nakamura 1999 reported two cases of somnolence and six cases of nausea in the ZNS group (N = 129), and seven cases of somnolence and two cases of nausea in the PB group (N = 126). Overall they reported 28/129 adverse effects in the ZNS group and 30/126 in the PB group. The North 1983 trial reported eight cases of rash, one case of involuntary movements, one hirsutism, one headache and one case of discomfort of the face in the PHT group (N = 140) compared to one case of rash, one dizziness and one nausea in the PCB group (N = 141). Franceschetti 1990 reported minimal data on the adverse effects, only that 3/10 people in the PHT group and 1/10 people in the PB group experienced neurological side effects. No data from the remaining trials were provided (Foy 1992; Lee 1989) . In the Fuller 2013 trial, a total of 22 people taking LEV experienced adverse events, eight experienced lethargy/tiredness or asthenia, four people experienced rash, one person had delirium, one had headache, one had pruritus and seven experienced mood/irritability problems. In the PHT group a total of 18/42 people experienced adverse events, ataxia (n = 1), nausea (n = 1), rash/itch (n = 5), drug intoxication (n = 2), anaphylaxis (n = 2), thrombophlebitis (n = 3), mood/irritability problems (n = 3) and lethargy/tiredness/asthenia (n = 1).
D I S C U S S I O N Summary of main results
The trials included in this Cochrane Review were all RCTs investigating the effects of a range of AEDs given either immediately before or after a craniotomy procedure to people with no previous history of seizures or exposure to AEDs. The underlying pathologies for craniotomy surgery were mixed within the studies (e.g. tumour, abscess, meningioma), with a small percentage of patients having surgery as a result of head injuries. One study included a substantial proportion (210/374) of head-injury patients (Lee 1989 ). This is a major limitation of this review as the objective is to examine outcomes for patients undergoing craniotomy presenting with non-trauma pathology. We acknowledge the possibility of differences in the risk of seizure post surgery depending on the underlying pathology of the patient. For the outcome of incidence of seizures, overall most trials reported no significant difference between treatment with AEDs and no treatment or treatment with AEDs and no treatment. Headto-head drug comparisons also yielded non-statistically significant results. Only two trials reported any statistically significant findings. In Fuller 2013, significantly more people experienced early seizures in the LEV group compared to the PHT group (P = 0.01). In North 1983, the incidence of early seizures was reduced in the AED group (PHT) compared to PCB (P < 0.05). Overall, the majority of results from the individual trials showed few significant differences between AED treatment participants and control participants for outcomes relevant to the number of death and adverse effects. However, two trials did show significant differences for adverse event outcomes (Fuller 2013; Wu 2013) . None of the included trials examined the functional outcome of patients.
Overall completeness and applicability of evidence
We were unable to meta-analyse any of the data and structuring a narrative summary was difficult for a number of reasons: few trials were available under each comparison examined (see Data synthesis for list of comparisons under investigation) and the interventions varied substantially with regards to duration of treatment period, dose and method of drug administration, country, methodological rigour and underlying pathologies. Trials differed regarding their reporting of outcomes, not all trials differentiated between early and late seizures and information about adverse effects of treatment was very limited. Most trials had similar inclusion and exclusion criteria. Patients undergoing supratentorial craniotomy were randomised in six of the eight included trials, but Fuller 2013 and Nakamura 1999 did not specify the type of surgery.
Quality of the evidence
The outcome of the risk of bias assessments conducted for each trial are noteworthy. We rated most trials as unclear on several of the criteria. Only two of the eight trials were rated at low in bias due to the method used to generate the randomisation sequence (Beenen 1999; Foy 1992) and only one trial used adequate methods for concealing the allocation of intervention (Beenen 1999). Most trials used adequate methods for blinding participants and outcome assessors; however, one trial was unblinded (Foy 1992) and therefore we rated it at high risk of bias for this criteria. There were no protocols available for any of the trials, therefore assessing selective reporting across trials was rated as unclear. We rated several trials as unclear as to how missing data were managed within their analyses. In most cases trials reported attrition and described the reasons for withdrawal.
Potential biases in the review process
We did not identify any biases in the review process.
Agreements and disagreements with other studies or reviews
A systematic review published in 1996 (Kuijlen 1996) assessed the effectiveness of prophylactic AED use in people undergoing supratentorial craniotomies. The review included three studies (Foy 1992; Lee 1989; North 1983 ) that were considered to be of satisfactory methodological quality. Odds ratios were calculated as a means of assessing the degree of association between treatment and the incidences of convulsions. The results of pooling the data from these three trials demonstrated no statistically significant difference between prophylaxis with AEDs and no treatment. The authors noted that there were only a small number of studies available in this area.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Our results from this review show that there is not enough evidence of sufficient quality available to suggest that AED treatment can or cannot be recommended to reduce post-craniotomy seizures. There is no evidence on which to base clinical practice.
Implications for research
More trials are needed to evaluate the effectiveness of prophylactic treatment with AEDs in preventing seizures following cranial surgery better. These trials must address the methodological weaknesses and protocol inconsistencies we identified within this review including:
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Beenen 1999
Methods Randomised double-blind, PCB-controlled, single-centre (Netherlands), parallel trial. 2 treatment arms: phenytoin (PHT) and valproate (VAL). Allocation concealed using sealed envelopes, trial medication identical in pre-coded packaged materials. Treatment period: 12 months Participants Adults aged 21 to 78 (mean age in PHT arm = 55 years, mean age in VAL arm = 51 years). Overall 47 males and 53 females, all patients undergoing craniotomy for different pathological conditions. Patients were not taking AEDs prior to randomisation and had no history of seizures. 100 randomised: 50 to PHT and 50 to VAL Interventions Group 1: PHT 100 mg intravenous 3 times daily administered immediately post-operation in recovery room Group 2: VAL 500 mg intravenous 3 times daily administered immediately post-operation in recovery room Patients took medication in oral form as soon as was possible for 12 months Outcomes Primary outcome: drug efficacy (number of seizures). Secondary outcomes: tolerability (number of withdrawals, adverse effects), quality of life and cognitive functioning Notes Intention-to-treat (ITT) analysis employed for primary outcome, not for other outcomes (quality of life)
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk Study used computer-generated randomisation method.
Allocation concealment (selection bias) Low risk Sealed envelopes, pre-coded and packaged medication.
Blinding of participants and personnel (performance bias) All outcomes Unclear risk Methods of sequence generation not described. Block randomisation was reported as used. However, the paper reports that early during data collection the contractor communicated that allocation was as follows: each 10 sequentially recruited patients were not internally randomised but received the same drug, determined by hatdraw at enrolment of the first patient in each block, with eight blocks of 10 patients then two blocks of four to be randomised with equal probability. At study completion, impact of allocation procedure on bias was assessed by statistical comparison of baseline patient characteristics, with similar age and gender distribution and proportion of serious pathologies and death from underlying pathology found between treat- 
D A T A A N D A N A L Y S E S
This review has no analyses. Results from these trials reported the number of patients who had seizures out of the number of patients randomised. However loss to follow-up during the trial was unclear. 2 Results from the trials only reported the number of patients who had seizures out of the number of patients who were followed up. Foy et al followed up 39 patients for late seizures. Franceschetti reported combination of PB and PHT results, cannot differentiate between groups on seizure outcome for all seizures and early seizures. 
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We were unable to make all the intended comparisons specified in the protocol due to lack of data.
